What do systematic reviews say?

Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval

• Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV‐related… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 481 participants
  Low

Direct oral anticoagulant secondary prophylaxis vs Low molecular weight heparin secondary prophylaxis

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 0.97 [0.83, 1.14]
  5 studies · 2854 participants
  Low

Idraparinux secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Idraparinux secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (moderate certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 1.11 [0.78, 1.59]
  1 study · 284 participants
  Moderate

Direct oral anticoagulant secondary prophylaxis vs vitamin K antagonist secondary prophylaxis

Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with vitamin K antagonist secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 0.94 [0.72, 1.23]
  4 studies · 1060 participants
  Low

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (time‐to‐event) compared with vitamin K antagonist secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  HR 0.94 [0.74, 1.2]
  2 studies · 1243 participants
  Low

Low molecular weight heparin vs vitamin K antagonist secondary prophylaxis

Low molecular weight heparin secondary prophylaxis showed no clear difference in all‐cause mortality (main analysis ‐ active cancer) compared with vitamin K antagonist secondary prophylaxis (low certainty).

• Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer 2018 · Cochrane Headline outcomes only
  RR 0.99 [0.88, 1.12]
  4 studies · 1712 participants
  Low